Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 1998

View Archived Issues

Company Profile: Introgen Therapeutics

T Cell Sciences receives patent on new compound

New anticancer agent capable of eluding tumor resistance mechanisms

C. pneumoniae antibody titers correlated to stroke and cerebral ischemia

NOS inhibition with L-NMMA reduces CBF in humans

Cortex: Q2 fiscal 1998 highlights

Electroporation therapy results in at least 80% reduction in tumor volume in preclinical studies

Neurocrine Biosciences: Q4 and FY 1997 highights

TRH ineffective as treatment for lung problems in premature infants

Osiris and the University of Cincinnati expand collaboration in tendon regeneration

Biosearch Italia and Versicor establish infectious disease collaboration

Biogen sets up Canadian office to promote local development of Avonex

FDA advisory committee to vote on expanded label for CEPRATE SC System

Selective inhibitor of p38 MAP kinase effective in chronic inflammatory diseases

Nucleoside with potent and selective anti-HIV and anti-HBV activity

Tedisamil has favorable profile as myocardial antiischemic agent

Azithromycin prevents acceleration of atherosclerosis by C. pneumoniae infection

Roche acquisition of Corange approved by U.S. regulators

Another market introduction for Aricept

Lead compound from ABS shows promise for neurodegenerative disorders

Nonsteroidal human progesterone receptor agonists developed at Ligand

Improved vision in AMD patients in phase I/II using PhotoPoint technology

Dolasetron now available in U.S.

Orthovisc PMA accepted for filing by FDA

Glycomed antiinflammatory patents licensed to Cytel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.